Cargando…

Tratamiento farmacológico en tiempos de incertidumbre: uso de la hidroxicloroquina/cloroquina en el tratamiento de COVID-19

BACKGROUND AND OBJECTIVES: : In this moments, of extreme gravity in which we find ourselves, and in the uncertainty face about the most effective treatment against COVID-19 disease and with the aim of find the evidence that support the chloroquine/hydroxychloroquine use recommendation to treat COVID...

Descripción completa

Detalles Bibliográficos
Autores principales: Mayayo-Vicente, S., Rodriguez Salvanés, F., Gallego-Arenas, A., Sánchez-Gómez, L.M., Ruiz-López, M., Sierra García, B., Jurado-López, A., Arriola-Bolado, P., Cervera Cano, M., Novella-Arribas, B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Sociedad Española de Médicos de Atención Primaria (SEMERGEN). Published by Elsevier España, S.L.U. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7837044/
https://www.ncbi.nlm.nih.gov/pubmed/32739134
http://dx.doi.org/10.1016/j.semerg.2020.06.016
_version_ 1783642877040001024
author Mayayo-Vicente, S.
Rodriguez Salvanés, F.
Gallego-Arenas, A.
Sánchez-Gómez, L.M.
Ruiz-López, M.
Sierra García, B.
Jurado-López, A.
Arriola-Bolado, P.
Cervera Cano, M.
Novella-Arribas, B.
author_facet Mayayo-Vicente, S.
Rodriguez Salvanés, F.
Gallego-Arenas, A.
Sánchez-Gómez, L.M.
Ruiz-López, M.
Sierra García, B.
Jurado-López, A.
Arriola-Bolado, P.
Cervera Cano, M.
Novella-Arribas, B.
author_sort Mayayo-Vicente, S.
collection PubMed
description BACKGROUND AND OBJECTIVES: : In this moments, of extreme gravity in which we find ourselves, and in the uncertainty face about the most effective treatment against COVID-19 disease and with the aim of find the evidence that support the chloroquine/hydroxychloroquine use recommendation to treat COVID-19 disease, a systematic review of published studies and RCT studies publishes until April 28, 2020 was carried out. MATERIAL AND METHODS: A systematic search was carried out in PubMed with the keywords COVID-19 and their synonyms and hydroxychloroquine/chloroquine. The data selection and extraction was elaborated by two researchers, independently. The results were discussed with a Primary Care physicians clinical group and the results were synthesized using GRADE methodology. RESULTS: A good quality systematic review was found that includes articles with a high risk of bias. And 8 EC launched that will produce results beyond May 2020. CONCLUSIONS: Although the conclusions of the systematic review generate a low confidence in the results, and the clinical variables that show benefit are intermediate variables, the side effects are acceptable and could be minimized with the use of QT lengthening risk tools, so it is could make a weak recommendation in favor of the use of chloroquine/hydroxychloroquine in patients with mild-moderate stage COVID-19.
format Online
Article
Text
id pubmed-7837044
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Sociedad Española de Médicos de Atención Primaria (SEMERGEN). Published by Elsevier España, S.L.U.
record_format MEDLINE/PubMed
spelling pubmed-78370442021-01-26 Tratamiento farmacológico en tiempos de incertidumbre: uso de la hidroxicloroquina/cloroquina en el tratamiento de COVID-19 Mayayo-Vicente, S. Rodriguez Salvanés, F. Gallego-Arenas, A. Sánchez-Gómez, L.M. Ruiz-López, M. Sierra García, B. Jurado-López, A. Arriola-Bolado, P. Cervera Cano, M. Novella-Arribas, B. Semergen Original BACKGROUND AND OBJECTIVES: : In this moments, of extreme gravity in which we find ourselves, and in the uncertainty face about the most effective treatment against COVID-19 disease and with the aim of find the evidence that support the chloroquine/hydroxychloroquine use recommendation to treat COVID-19 disease, a systematic review of published studies and RCT studies publishes until April 28, 2020 was carried out. MATERIAL AND METHODS: A systematic search was carried out in PubMed with the keywords COVID-19 and their synonyms and hydroxychloroquine/chloroquine. The data selection and extraction was elaborated by two researchers, independently. The results were discussed with a Primary Care physicians clinical group and the results were synthesized using GRADE methodology. RESULTS: A good quality systematic review was found that includes articles with a high risk of bias. And 8 EC launched that will produce results beyond May 2020. CONCLUSIONS: Although the conclusions of the systematic review generate a low confidence in the results, and the clinical variables that show benefit are intermediate variables, the side effects are acceptable and could be minimized with the use of QT lengthening risk tools, so it is could make a weak recommendation in favor of the use of chloroquine/hydroxychloroquine in patients with mild-moderate stage COVID-19. Sociedad Española de Médicos de Atención Primaria (SEMERGEN). Published by Elsevier España, S.L.U. 2020-08 2020-07-11 /pmc/articles/PMC7837044/ /pubmed/32739134 http://dx.doi.org/10.1016/j.semerg.2020.06.016 Text en © 2020 Sociedad Española de Médicos de Atención Primaria (SEMERGEN). Published by Elsevier España, S.L.U. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Original
Mayayo-Vicente, S.
Rodriguez Salvanés, F.
Gallego-Arenas, A.
Sánchez-Gómez, L.M.
Ruiz-López, M.
Sierra García, B.
Jurado-López, A.
Arriola-Bolado, P.
Cervera Cano, M.
Novella-Arribas, B.
Tratamiento farmacológico en tiempos de incertidumbre: uso de la hidroxicloroquina/cloroquina en el tratamiento de COVID-19
title Tratamiento farmacológico en tiempos de incertidumbre: uso de la hidroxicloroquina/cloroquina en el tratamiento de COVID-19
title_full Tratamiento farmacológico en tiempos de incertidumbre: uso de la hidroxicloroquina/cloroquina en el tratamiento de COVID-19
title_fullStr Tratamiento farmacológico en tiempos de incertidumbre: uso de la hidroxicloroquina/cloroquina en el tratamiento de COVID-19
title_full_unstemmed Tratamiento farmacológico en tiempos de incertidumbre: uso de la hidroxicloroquina/cloroquina en el tratamiento de COVID-19
title_short Tratamiento farmacológico en tiempos de incertidumbre: uso de la hidroxicloroquina/cloroquina en el tratamiento de COVID-19
title_sort tratamiento farmacológico en tiempos de incertidumbre: uso de la hidroxicloroquina/cloroquina en el tratamiento de covid-19
topic Original
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7837044/
https://www.ncbi.nlm.nih.gov/pubmed/32739134
http://dx.doi.org/10.1016/j.semerg.2020.06.016
work_keys_str_mv AT mayayovicentes tratamientofarmacologicoentiemposdeincertidumbreusodelahidroxicloroquinacloroquinaeneltratamientodecovid19
AT rodriguezsalvanesf tratamientofarmacologicoentiemposdeincertidumbreusodelahidroxicloroquinacloroquinaeneltratamientodecovid19
AT gallegoarenasa tratamientofarmacologicoentiemposdeincertidumbreusodelahidroxicloroquinacloroquinaeneltratamientodecovid19
AT sanchezgomezlm tratamientofarmacologicoentiemposdeincertidumbreusodelahidroxicloroquinacloroquinaeneltratamientodecovid19
AT ruizlopezm tratamientofarmacologicoentiemposdeincertidumbreusodelahidroxicloroquinacloroquinaeneltratamientodecovid19
AT sierragarciab tratamientofarmacologicoentiemposdeincertidumbreusodelahidroxicloroquinacloroquinaeneltratamientodecovid19
AT juradolopeza tratamientofarmacologicoentiemposdeincertidumbreusodelahidroxicloroquinacloroquinaeneltratamientodecovid19
AT arriolaboladop tratamientofarmacologicoentiemposdeincertidumbreusodelahidroxicloroquinacloroquinaeneltratamientodecovid19
AT cerveracanom tratamientofarmacologicoentiemposdeincertidumbreusodelahidroxicloroquinacloroquinaeneltratamientodecovid19
AT novellaarribasb tratamientofarmacologicoentiemposdeincertidumbreusodelahidroxicloroquinacloroquinaeneltratamientodecovid19